Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025

Liminatus Pharma, Inc.

IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.
Preclinical data show IBA101 plus PD-1/PD-L1 inhibitors gave 2-3x higher complete response rates vs monotherapy.
IND preparation begins H2 2025 with simultaneous submissions to U.S. FDA and Korea MFDS planned.
Phase 1 first-in-human study in advanced solid tumors (starting with NSCLC) expected to launch in late 2026.
Company completed SPAC merger with IRIS Acquisition Corp. and began trading on Nasdaq in May 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.